Valerion Therapeutics, LLC (formerly 4S3 Bioscience) is a biotechnology company utilizing a proprietary antibody-mediated delivery platform to target therapies to specific tissues via a well-known and broadly studied transport pathway. This platform is capable of enhanced intracellular delivery of a variety of active therapeutic payloads via a transport mechanism that is present in muscle and neurons and elevated in certain types of cancer. Pipeline candidates include therapeutic agents aimed at addressing a host of orphan genetic disorders with limited or no current therapies. Valerion is currently targeting Pompe disease, Lafora disease, and Myotubular myopathy.

Graduated in 2011